Research and Development
Development of Mito-NASH-03 and Mito-T2D-53 for NASH and type 2 diabetes, respectively
Proof-of-concept studies of Mito BioPharma technology on NASH and type 2 diabetes have been validated in multiple mouse model systems. For testing efficacy on NASH, HFD (high fat diet) model (for efficacy on steatosis), HFD and high cholesterol diet model (for efficacy on steatosis, inflammation, and fibrosis), and CCl4model (for efficacy on fibrosis) have been evaluated. For testing efficacy on type 2 diabetes, HFD and db/db mouse models have been used.
Mito-NASH-03 and Mito-T2D-53, exhibited excellent pharmacology, ADME, PK/PD, and toxicology profiles, and have been selected as potential IND leads for type 2 diabetes and NASH respectively.
Medicinal Chemistry Research for Expanding Drug Candidate Pipeline
Mito BioPharma has developed a number of chemical classes with distinct pharmacodynamic properties, including their impact on oxygen consumption, mitochondrial membrane potential, ATP synthesis and ATP level, and plasma membrane potential. Moreover, Mito Biopharma has proprietary know-how in SAR and is producing a repertoire of leads in each PD group with diverse ADME, PK, toxicology properties. These leads are being tested and validated as potential leads for other indications, including HCC (hepatocellular carcinoma), metastatic colon cancer, metastatic pancreatic cancer, ALL (acute leukocytic leukemia), and AML (acute myeloid leukemia).
The biological research team has performed extensive proof-of-concept studies to validate the mechanism of action on the various indications in clinically relevant animal models. Below are the example studies which are published that demonstrated the effectiveness of the mechanism of action on type 2 diabetes and metastatic colon cancer. In addition, the biological research team is working closely with medicinal chemistry team to expand the drug candidate repertoire and testing new leads. Similar comprehensive efficacy studies have been conducted with various testing compounds to select leads in various indications including NASH, type 2 diabetes, metastatic colon cancer, metastatic pancreatic cancer, and ALL.
Publications (click to review)